Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanghai Rongsheng Biotech's Freeze-dried Human Rabies Vaccine (Vero cells) is an inactivated vaccine developed for the prevention of rabies. Produced using Vero cell culture technology, the vaccine is designed to elicit a protective neutralizing antibody response against the rabies virus. It has successfully completed Phase III clinical trials in China, demonstrating safety and immunogenicity using the 'Essen' (5-dose) immunization schedule in healthy individuals aged 10 to 60 years. The vaccine is currently approved and in the commercial production stage in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Freeze-dried Human Rabies Vaccine (Vero cells).